MindMed CFO David Guebert retiring Mar 31; director Vinson not seeking re-election; exec comp increases

Definium Therapeutics, Inc.

CFO David Guebert's last day is March 31, 2022; search for new CFO launched with executive search firm.
Director Sarah Y. Vinson will not stand for re-election at 2022 Annual Meeting; no disagreement cited.
Board reduces size from 6 to 5 effective at 2022 Annual Meeting.
CEO Robert Barrow base salary increased to $565,000, plus $233,411 cash bonus and equity awards.
Executive President Miri Halperin Wernli base salary raised to $390,000 with 40% target bonus.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David D. Guebert

Chief Financial Officer

DFTX · Definium Therapeutics, Inc.

Effective: 2022-03-31
Filed: March 25, 2022, 7:59 PM ET

On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.

Departed

Sarah Y. Vinson

Director

DFTX · Definium Therapeutics, Inc.

Filed: March 25, 2022, 7:59 PM ET

On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David D. Guebert departed as Chief Financial Officer at Definium Therapeutics, Inc..

Action: separation from the Company
Role: Chief Financial Officer

Exact text from the filing

On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Y. Vinson departed as Director at Definium Therapeutics, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-085330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.